Clinical Trials
71 trialsDUAL-OV-CAR-NK
Beijing Biotech
T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors
University of Pittsburgh
EB-DUALNK-OV
Beijing Biotech
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
MK-2870-001
Klus Pharma Inc.
OVATION 2
Imunon
ERADIC8
858 Therapeutics, Inc.
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Blue Earth Diagnostics
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
Case Comprehensive Cancer Center
DUAL-OV-CAR-NK
Beijing Biotech
FORTITUDE-301
Amgen
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
NEODOC
Radboud University Medical Center
A Study of PF-06873600 in People With Cancer
Pfizer
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
ABILITY-1
Medicenna Therapeutics, Inc.
Surgery for Relapsed Ovarian Cancer in Precision
Shanghai Gynecologic Oncology Group
KANDOVA
Novakand Pharma AB
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pfizer
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe, Inc.
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Opna Bio LLC
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors
Valerio Therapeutics
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Elucida Oncology
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
ImmunoGen, Inc.
OVHM-01
University Health Network, Toronto
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Syndax Pharmaceuticals
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Pfizer
Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients
University of Wisconsin, Madison
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
Corcept Therapeutics
ORION-01
National Cancer Centre, Singapore
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
ORION-02
National Cancer Centre, Singapore
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients
Oslo University Hospital
Trientine
National Cheng-Kung University Hospital
A Study LY2228820 for Recurrent Ovarian Cancer
Eli Lilly and Company
GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer
Medical University Innsbruck
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer
University of Texas Southwestern Medical Center
Veli-BRCA
Vejle Hospital
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
MEI Pharma, Inc.
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
National Cancer Institute (NCI)
Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer
University Hospital Heidelberg
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
Valerio Therapeutics
Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
Vejle Hospital